和黄医药(HCM)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

HCM 和黄医药

盘前交易 12-15 04:51:51 EST

13.42

-0.18

-1.32%

最高13.79	最低13.42	成交量1.46万
今开13.79	昨收13.60	日振幅2.72%
总市值23.41亿	流通市值13.96亿	总股本1.74亿
成交额19.80万	换手率0.01%	流通股本1.04亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"HCM","market":"US","secType":"STK","nameCN":"和黄医药","latestPrice":13.42,"timestamp":1765573200000,"preClose":13.6,"halted":0,"volume":14563,"delay":0,"floatShares":104000000,"shares":174433934,"eps":2.649215,"marketStatus":"盘前交易","change":-0.18,"latestTime":"12-15 04:51:51 EST","open":13.79,"high":13.79,"low":13.42,"amount":197968.271523,"amplitude":0.027206,"askPrice":17.23,"askSize":100,"bidPrice":13.3,"bidSize":100,"shortable":3,"etf":0,"ttmEps":2.649215,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1765809000000},"marketStatusCode":1,"adr":1,"adrRate":5,"listingDate":1458187200000,"exchange":"NASDAQ","adjPreClose":13.42,"postHourTrading":{"tag":"盘后","latestPrice":13.42,"preClose":13.42,"latestTime":"19:10 EST","volume":10,"amount":134.47,"timestamp":1765584644604},"volumeRatio":0.7685650348624086,"impliedVol":0.2275,"impliedVolPercentile":0.3213},"requestUrl":"/m/hq/s/HCM","defaultTab":"news","newsList":[{"id":"2589804367","title":"和黄医药(00013)：达唯珂®(TAZVERIK®)获纳入首版国家商业健康保险创新药品目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2589804367","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589804367?lang=zh_cn&edition=full","pubTime":"2025-12-08 08:13","pubTimestamp":1765152816,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和黄医药(00013)发布公告，经过与中国国家医疗保障局(国家医保局)的医保续约，爱优特®(ELUNATE®)、沃瑞沙®(ORPATHYS®)和苏泰达®(SULANDA®)将继续获纳入自2026年1月1日起生效的新版《国家基本医疗保险、工伤保险和生育保险药品目录》(国家医保药品目录)。此外，达唯珂®(TAZVERIK®)获纳入首版国家商业健康保险创新药品目录(简称商保创新药目录)。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378561.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1587","BK1191","BK4531","BK4588","HCM","00013","BK4585","BK1588","BK4007"],"gpt_icon":0},{"id":"2586729952","title":"和黄医药(00013)将于2025年欧洲肿瘤内科学会 (ESMO) 亚洲年会和 2025年美国血液学会 (ASH) 年会公布临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2586729952","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586729952?lang=zh_cn&edition=full","pubTime":"2025-11-27 08:05","pubTimestamp":1764201920,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和黄医药 公布，和黄医药自主研发的化合物的数项研究的最新及更新后的数据将于2025年12月5日至7日在新加坡召开的欧洲肿瘤内科学会亚洲年会，以及 2025年12月6日至9日在美国奥兰多召开的美国血液学会年会上公布。抗CD47单克隆抗体HMPL-A83用于治疗晚期实体瘤的首个人体临床试验结果，以及呋喹替尼 联合信迪利单抗用于二线治疗局部晚期或转移性肾细胞癌的FRUSICA-2注册研究中II期部分的结果将于 2025年ESMO亚洲年会公布。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1374212.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4109","BK4007","BK4531","BK4585","LU2463526074.USD","ASH","BK4588","BK1588","HCM","BK1587","00013","BK1191"],"gpt_icon":0},{"id":"2582317693","title":"年内股价涨幅收窄至5%，“躲过牛市”的和黄医药(00013)何时反弹？","url":"https://stock-news.laohu8.com/highlight/detail?id=2582317693","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582317693?lang=zh_cn&edition=full","pubTime":"2025-11-12 10:11","pubTimestamp":1762913496,"startTime":"0","endTime":"0","summary":"今年以来，在港股创新药牛市带动下，恒生医疗保健指数年初至今最高涨幅达到102.6%，即使经过10月以来的大幅回调，该涨幅也有70.57%。相较之下，手握3款商业化创新药并拥有首创抗体靶向偶联药物的和黄医药却似乎“被市场遗忘”。该公司股价今年年初至今最高涨幅仅36.36%，并且“跟跌不跟涨”，在近期港股创新药板块整体回调期涨幅继续收窄至仅剩5.19%。8月7日美股盘前，和黄医药公布了其2025年中报业绩。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1368108.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","HCM","BK4585","00013","BK1587","BK1588","BK1191","BK4531","BK4007"],"gpt_icon":0},{"id":"2582484474","title":"东方证券：维持和黄医药(00013)“买入”评级 全新ATTC平台激发创新活力","url":"https://stock-news.laohu8.com/highlight/detail?id=2582484474","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582484474?lang=zh_cn&edition=full","pubTime":"2025-11-10 14:17","pubTimestamp":1762755461,"startTime":"0","endTime":"0","summary":"公司近期举办研发日活动，介绍癌症和免疫疾病治疗方面的最新进展，包括全新ATTC平台以及管线情况。首个候选药物初步展现全面的抗肿瘤活性HMPL-A251为ATTC平台中的首款候选药物，将PI3K/PIKK抑制剂作为有效载荷与HER2抗体偶联，因此该药物同时靶向HER2和PI3K通路，起到协同抗肿瘤作用。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1367152.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["600958","03958","HCM","00013"],"gpt_icon":0},{"id":"2581023150","title":"中金：维持和黄医药(00013)跑赢行业评级 目标价30港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2581023150","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581023150?lang=zh_cn&edition=full","pubTime":"2025-11-07 09:16","pubTimestamp":1762478212,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中金发布研报称，基本维持和黄医药2025年/2026年归母净利润预测3.66亿美元/0.35亿美元。该行维持跑赢行业评级，基于DCF模型，维持目标价30港币不变，较当前股价有23.9%的上行空间。此外，公司预计将于1H26和2H26分别启动另外两个ATTC分子A580和A830的中美I期研究。ATTC首个候选分子HMPL-A251于研发日公开亮相，早期数据展现潜力ATTC为和黄医药利用其长期以来在小分子领域的经验探索的新颖药物形式。该行认为其有望成为乳腺癌和多种癌种的潜力疗法。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1366378.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HCM","00013"],"gpt_icon":0},{"id":"2581738799","title":"和黄医药(00013)宣布沃瑞沙®和泰瑞沙®联合疗法用于治疗泰瑞沙®治疗后疾病进展的伴有 MET过表达和/或扩增的特定肺癌患者的SAFFRON全球III期研究完成患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2581738799","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581738799?lang=zh_cn&edition=full","pubTime":"2025-11-05 08:13","pubTimestamp":1762301600,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和黄医药 发布公告，宣布SAFFRON研究已完成患者入组。SAFFRON研究一项开放标签、随机、全球多中心III期研究，旨在评估沃瑞沙联合泰瑞沙口服治疗对比铂类双药化疗用于治疗接受一线或二线泰瑞沙治疗作为最近的治疗后疾病进展的EGFR突变、伴有MET过表达和/或扩增的局部晚期或转移性非小细胞肺癌。若取得理想的结果，其数据将有望支持向全球监管机构提交沃瑞沙和泰瑞沙联合疗法的监管注册申请。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1365327.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4531","BK4162","BK4585","BK4588","BK1588","BK4134","LU1496350502.SGD","BK1191","III","HCM","00013","LU1989772840.SGD","LU1291159041.SGD","LU1989771016.USD","MET","LU1989772923.USD","BK4007","BK1587"],"gpt_icon":0},{"id":"2580725271","title":"和黄医药(00013.HK)涨超3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2580725271","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580725271?lang=zh_cn&edition=full","pubTime":"2025-11-04 10:31","pubTimestamp":1762223460,"startTime":"0","endTime":"0","summary":"每经AI快讯，和黄医药(00013.HK)涨超3%，截至发稿，涨2.95%，报24.46港元，成交额6552.25万港元。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2025-11-04/doc-infwfawx0552315.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-11-04/doc-infwfawx0552315.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1191","BK4585","BK1587","00013","BK1588","HCM","BK4007","BK4531","BK4588"],"gpt_icon":0},{"id":"2580429840","title":"美股异动丨和黄医药盘前涨超2%，预计年底推动候选药物HMPL-A251进入临床开发阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2580429840","media":"中金财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580429840?lang=zh_cn&edition=full","pubTime":"2025-11-03 17:27","pubTimestamp":1762162023,"startTime":"0","endTime":"0","summary":"和黄医药盘前涨超2%，报15美元；H股今日收涨2.15%，报23.76港元。　　消息面上，和黄医药日前举办了投资者会议，分享其创新ATTC平台及一系列产品最新关键研发和业务进展。其中ATTC平台首个候选药物HMPL-A251，在体外实验中其PI3K/PIKK抑制剂有效载荷在多种肿瘤细胞系中展现出高选择性和强效的抗肿瘤活性。和黄医药计划采取以数据为导向的策略，从2025年底开始推动HMPL-A251进入临床开发，初期研究将评估该候选药物在伴有不同HER2及PAM改变状态的多个瘤种中的表现。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20251103/31762965.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1587","BK4585","BK4007","BK1191","HCM","BK4531","BK4588","BK1588","00013"],"gpt_icon":0},{"id":"2580723774","title":"和黄医药(00013)举办最新研发进展投资者会议分享产品管线及业务进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2580723774","media":"智通财经","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580723774?lang=zh_cn&edition=full","pubTime":"2025-11-03 08:06","pubTimestamp":1762128413,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和黄医药(00013)发布公告，于2025年10月31日举行的投资者会议中分享最新关键研发和业务进展。此次活动重点展示了和黄医药在推进创新癌症和免疫疾病治疗方面的最新进展，包括介绍其新一代抗体靶向偶联药物(ATTC)平台，以及后期管线候选药物的最新进展。和黄医药研发负责人兼首席医学官石明博士表示：“满足癌症和免疫疾病领域关键未被满足的医学需求是和黄医药的使命所在，驱动着我们持续致力推进创新疗法。ATTC平台有望重新定义癌症精准治疗，依托我们坚实的产品管线和合作策略，我们有信心能够为全球患者提供具有潜在变革性的癌症和免疫疾病治疗方案。”","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1364205.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1587","BK4007","BK4588","BK1191","00013","BK4585","HCM","BK1588","BK4531"],"gpt_icon":0},{"id":"2577524346","title":"和黄医药(00013)于AACR-NCI-EORTC分子靶向和癌症治疗国际会议上公布HMPL-A251数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2577524346","media":"智通财经网","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577524346?lang=zh_cn&edition=full","pubTime":"2025-10-23 08:18","pubTimestamp":1761178705,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和黄医药 发布公告，于2025年10月22至26日在美国波士顿举行的 AACR-NCI-EORTC分子靶向和癌症治疗国际会议上公布HMPL-A251的临床前数据。当与HER2 阳性细胞共同培养时，HMPL-A251还对HER2无表达细胞展现出旁观者效应。和黄医药计划于2025年底启动HMPL-A251的全球临床试验，并于2026年提交多项其他ATTC候选药物的全球新药临床试验申请。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1358485.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1587","NCI","BK1588","BK4202","BK4588","BK1191","00013","HCM","BK4585","BK4531","BK4007"],"gpt_icon":0},{"id":"2575262630","title":"和黄医药(00013)：陈邵文获委任为独立非执行董事及技术委员会成员","url":"https://stock-news.laohu8.com/highlight/detail?id=2575262630","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575262630?lang=zh_cn&edition=full","pubTime":"2025-10-14 16:31","pubTimestamp":1760430703,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和黄医药(00013)发布公告，陈邵文教授获委任为公司独立非执行董事及技术委员会成员，自2025年10月15日起生效。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1354761.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK4007","BK1588","HCM","BK4585","BK4588","BK4531","BK1587","00013"],"gpt_icon":0},{"id":"2575742572","title":"和黄医药(00013)将于2025年欧洲肿瘤内科学会年会公布FRUSICA-2注册研究数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2575742572","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575742572?lang=zh_cn&edition=full","pubTime":"2025-10-13 12:09","pubTimestamp":1760328598,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和黄医药 发布公告，公布呋喹替尼联合信迪利单抗用于治疗局部晚期或转移性肾细胞癌患者的FRUSICA-2注册研究结果。该研究III期部分的结果将于2025年10月17日(星期五)在德国柏林举行的欧洲肿瘤内科学会年会上公布。基于FRUSICA-2研究的数据，中国国家药品监督管理局已受理呋喹替尼和信迪利单抗的联合疗法用于既往接受过系统治疗失败的局部晚期或转移性的肾细胞癌患者的新药上市申请。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1354144.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"和黄医药(00013)将于2025年欧洲肿瘤内科学会年会公布FRUSICA-2注册研究数据","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4531","00013","BK1588","HCM","BK4588","BK4007","BK1191","BK4585","BK1587"],"gpt_icon":0},{"id":"2572569239","title":"和黄医药(00013)将于2025年欧洲肿瘤内科学会 (ESMO) 年会公布临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2572569239","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2572569239?lang=zh_cn&edition=full","pubTime":"2025-10-02 08:08","pubTimestamp":1759363711,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和黄医药(00013)发布公告，该公司今日宣布将于2025年10月17日至21日在德国柏林召开的欧洲肿瘤内科学会2025年年会上公布和黄医药自主研发的化合物的数项研究的最新及更新后的数据。呋喹替尼(fruquintinib)联合信迪利单抗(sintilimab)用于二线治疗局部晚期或转移性肾细胞癌的FRUSICA-2注册研究结果将于迷你口头报告环节公布。此外，呋喹替尼用于治疗子宫内膜癌的FRUSICA-1研究，以及赛沃替尼 ( savolitinib)用于治疗非小细胞肺癌的SACHI和SAVANNAH研究的进一步分析结果将于海报展示环节公布。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1351797.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK4585","BK1587","BK1588","HCM","00013","BK4531","BK4588","BK4007"],"gpt_icon":0},{"id":"2566928850","title":"港股异动 | 医药股多数反弹 创新药再迎利好 多家药企称海外传闻不影响出海预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2566928850","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2566928850?lang=zh_cn&edition=full","pubTime":"2025-09-12 13:44","pubTimestamp":1757655876,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0417516738.SGD","09939","LU0348766576.USD","LU1794554557.SGD","LU2778985437.USD","LU0417516902.SGD","LU0348735423.USD","HCM","IE00B5MMRT66.SGD","LU0540923850.HKD","BK4526","LU0348825331.USD","159938","BK1191","09688","688428","LU0634319403.HKD","02157","LU2476274720.SGD","IE00BPRC5H50.USD","LU0348783233.USD","LU0561508036.HKD","06978","BK1515","LU1720050803.USD","BK4531","BK1574","LU2476274308.USD","BK4548","BK4585","LU0348767384.USD","LU0417516571.SGD","00013","BK4007","LU2488822045.USD","ZLAB","159992","BK1588","BK4139","BK4588","09926","09969","BK1161","IE00B543WZ88.USD","LU0348784397.USD","LU0348827113.USD","BK0239","BK1587"],"gpt_icon":0},{"id":"2566422709","title":"港股异动 | 和黄医药(00013.HK)涨超7% 将于下月底介绍最新研发进展 机构指其多个里程碑事件值得期待","url":"https://stock-news.laohu8.com/highlight/detail?id=2566422709","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2566422709?lang=zh_cn&edition=full","pubTime":"2025-09-12 11:57","pubTimestamp":1757649469,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"25aae963f1d5459eb6e8e1d01007b8cc","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4007","BK1587","00013","BK4588","BK4585","BK4531","HCM","BK1588","BK1191"],"gpt_icon":0},{"id":"2566442449","title":"昨日大跌后今日港股创新药概念股全线反弹。截至发稿康宁杰瑞制药-B涨超14%和黄医药涨超6%、再鼎医药、乐普生物B涨超5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2566442449","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2566442449?lang=zh_cn&edition=full","pubTime":"2025-09-12 11:27","pubTimestamp":1757647664,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"25aae963f1d5459eb6e8e1d01007b8cc","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1969619763.USD","LU2097828805.USD","YANG","HSCEI","LU2488822045.USD","688235","07226","LU2242644610.SGD","BK4588","BK1588","02157","LU2097828714.EUR","BK4007","BK4548","LU0502904849.HKD","LU2097828631.EUR","ONC","09966","BK1589","LU1719994722.HKD","BK0239","06978","LU2097828557.USD","159992","HSTECH","BK1583","BK4585","BK1500","BK4526","LU2097828474.EUR","09688","HCM","LU1251922891.USD","01801","LU0307460666.USD","01167","BK1161","00013","LU0588546209.SGD","LU1770034418.SGD","BK1587","BK1574","BK4139","06160","BK1191","LU2328871848.SGD","ZLAB","LU1303224171.USD","BK4614","LU0455707207.USD"],"gpt_icon":0},{"id":"2566948867","title":"和黄医药(00013)将于10月31日介绍最新研发进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2566948867","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2566948867?lang=zh_cn&edition=full","pubTime":"2025-09-12 08:08","pubTimestamp":1757635724,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和黄医药(00013)发布公告，将于2025年10月31日(星期五)在中国上海举办会议分享最新研发进展，并将通过网络同步直播。活动期间，和黄医药执行副总裁、研发负责人兼首席医学官石明博士将分享公司的研发策略和愿景，包括概述公司抗体靶向偶联药物(ATTC)平台并重点介绍其首个候选药物HMPL-A251，以及后期研发管线的最新进展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1344368.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","BK4531","BK1191","BK4585","BK1588","BK1587","BK4007","00013","HCM"],"gpt_icon":0},{"id":"2566921919","title":"美股异动 | 中概医药股上涨 再鼎医药(ZLAB.US)涨超14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2566921919","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2566921919?lang=zh_cn&edition=full","pubTime":"2025-09-11 22:41","pubTimestamp":1757601703,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0106831901.USD","IE00B19Z3581.USD","LU1868836914.USD","688235","LU2328871848.SGD","LU2471134796.USD","HCM","LU1894683348.USD","BK1515","BK4552","BK0239","BK4139","LU1303224171.USD","LU1791807156.HKD","ZLAB","BK1574","BK4531","LU0742534661.SGD","159938","LU1868837136.USD","LEGN","BK1587","LU1969619763.USD","LU0061475181.USD","06978","BK1191","BK4550","LU0048573561.USD","LU1868837300.USD","BK4516","06160","BK4007","LU0096364046.USD","LU1868836591.USD","BK1500","LU1894683264.USD","159992","ONC","BK4526","09688","LU1668664300.SGD","BK4505","LU2237443978.SGD","LU0251142724.SGD","09939","LU2237443465.HKD","LU2237443895.HKD","00013","IE00BFXG1179.USD","IE0004091025.USD"],"gpt_icon":0},{"id":"2565690185","title":"美股异动 | 和黄医药(HCM.US)涨逾6% 将公布自研化合物数项研究最新数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2565690185","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2565690185?lang=zh_cn&edition=full","pubTime":"2025-09-05 22:50","pubTimestamp":1757083808,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["SG9999001424.SGD","SG9999001440.SGD","LU1066051811.HKD","BK4560","IE00B3T34201.USD","IE00BKVL7J92.USD","IE00B1BXHZ80.USD","IE00BZ1G4Q59.USD","LU2237443549.SGD","LU1066051225.USD","CSCO","LU1674673691.USD","LU0203345920.USD","LU1894683264.USD","LU1221951046.USD","LU2237443465.HKD","LU2506952097.USD","SG9999002224.SGD","IE00BDGV0183.EUR","LU1066051498.USD","HCM","LU1046421795.USD","LU2286300806.USD","LU0348723411.USD","BK4515","LU0942090050.USD","LU1244550577.SGD","BK4588","LU0792757196.USD","LU0731783394.SGD","LU2506951958.HKD","BK4525","LU2237443978.SGD","LU0950375773.USD","LU0203347892.USD","LU1894683348.USD","BK4581","LU1778281490.HKD","LU1880398471.USD","LU2462157665.USD","BK4579","00013","LU1066053197.SGD","SG9999015945.SGD","SG9999015952.SGD","LU0823417737.USD","LU1674673428.USD","BK1191","BK4550","LU1430594728.SGD"],"gpt_icon":0},{"id":"2565310533","title":"港股异动 | 和黄医药(00013)涨超6% 将于2025年WCLC大会和CSCO年会上公布自研化合物数项研究最新数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2565310533","media":"智通财经","labels":["conferences","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2565310533?lang=zh_cn&edition=full","pubTime":"2025-09-05 10:58","pubTimestamp":1757041134,"startTime":"0","endTime":"0","summary":"消息面上，9月5日，和黄医药发布公告，将于2025年9月6日至9日在西班牙巴塞罗那召开的2025年世界肺癌大会，以及2025年9月10至14日在中国济南召开的中国临床肿瘤学会2025年年会上公布和黄医药自主研发的化合物的数项研究的最新及更新后的数据。HMPL-653在中国腱鞘巨细胞瘤患者中开展的首个人体I期临床试验数据将于2025年CSCO年会上首次公布。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1341851.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00013","BK4007","LU1066051498.USD","LU1599440770.SGD","LU1032955483.USD","HCM","LU1244550577.SGD","BK4531","LU2247934214.USD","IE00BFXG1179.USD","LU1066053197.SGD","LU1244550494.USD","LU2237443622.USD","LU1778281490.HKD","LU2237443549.SGD","LU2417539215.USD","BK4612","BK4515","IE00B1BXHZ80.USD","LU1585245621.USD","SG9999015952.SGD","LU1894683264.USD","LU2236285917.USD","LU1880398471.USD","LU2506951875.HKD","LU0234572021.USD","IE00BDGV0183.EUR","LU1059921491.USD","LU0792757196.USD","LU1506573853.SGD","LU2286300806.USD","CSCO","LU2506951958.HKD","BK4533","LU0868494708.USD","LU1046421795.USD","LU2456880835.USD","LU0203347892.USD","LU1235294995.USD","LU1894683348.USD","SG9999002232.USD","LU0868494617.USD","LU1267930813.SGD","IE000M9KFDE8.USD","IE00BVYPNV92.GBP","LU2237443465.HKD","SG9999015945.SGD","LU0203345920.USD","IE00BGHQF631.EUR","IE00B3PB1722.GBP"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.hutch-med.com","stockEarnings":[{"period":"1week","weight":-0.0563},{"period":"1month","weight":-0.1217},{"period":"3month","weight":-0.2515},{"period":"6month","weight":-0.2059},{"period":"1year","weight":-0.1544},{"period":"ytd","weight":-0.0687}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"和黄医药（中国）有限公司是一间主要从事制造及销售药物的投资控股公司。该公司主要通过两个分部运营业务。肿瘤免疫业务分部从事发现、开发和商业化用于治疗癌症和免疫性疾病的靶向疗法和免疫疗法。其中研发包括涵盖药物发现、开发、生产及监管职能的研发活动，上市产品包括通过研发活动开发的药物的已开具发票的销售、推广、生产及分销。其他业务分部从事其他商业化业务，包括其他处方药物及保健品的销售、推广、生产及分销。","yearOnYearQuotes":[{"month":1,"riseRate":0.222222,"avgChangeRate":-0.048009},{"month":2,"riseRate":0.444444,"avgChangeRate":0.016796},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.014296},{"month":4,"riseRate":0.5,"avgChangeRate":0.03686},{"month":5,"riseRate":0.4,"avgChangeRate":-0.069594},{"month":6,"riseRate":0.7,"avgChangeRate":0.077435},{"month":7,"riseRate":0.6,"avgChangeRate":0.053079},{"month":8,"riseRate":0.4,"avgChangeRate":0.002476},{"month":9,"riseRate":0.5,"avgChangeRate":-0.017634},{"month":10,"riseRate":0.5,"avgChangeRate":-0.007604},{"month":11,"riseRate":0.7,"avgChangeRate":0.110086},{"month":12,"riseRate":0.5,"avgChangeRate":-0.016268}],"exchange":"NASDAQ","name":"和黄医药","nameEN":"Hutchison China Meditech"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"和黄医药(HCM)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供和黄医药(HCM)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"和黄医药,HCM,和黄医药股票,和黄医药股票老虎,和黄医药股票老虎国际,和黄医药行情,和黄医药股票行情,和黄医药股价,和黄医药股市,和黄医药股票价格,和黄医药股票交易,和黄医药股票购买,和黄医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"和黄医药(HCM)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供和黄医药(HCM)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}